- Details
- Ashish Kamat engages with Jeffrey Ross to discuss the complexities of micropapillary urothelial carcinoma (MPUC), an aggressive subtype of urothelial bladder cancer. Kamat underscores the disease's frequent late-stage presentations, and Ross details the correlation between HER2 gene alterations and MPUC's aggressive behavior and early spread. The conversation also covers the potential of anti-HER2...
|
- Details
- Ashish Kamat hosts Petros Grivas to discuss the potential role of circulating tumor DNA (ctDNA) in managing minimal residual disease (MRD) in bladder cancer. Dr. Grivas highlights that early ctDNA detection could lead to timely treatments, potentially enhancing survival rates. He explains how ctDNA can help identify genomic alterations to steer treatment choices. Using various study data, he suppo...
|
- Details
- Leslie Ballas, Jason Efstathiou, and Alexandre Zlotta discuss the study Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis'. The research suggests TMT is as effective as radical cystectomy, exhibiting no significant disparity in five-year survival rates. This implies TMT could be a valuable alternat...
|
- Details
- Zach Klaassen interviews Sarah Psutka about her Phase I/II trial focusing on using acupuncture to mitigate the toxic effects of Bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer. Psutka explains that while BCG is an essential treatment for high-risk cases, it triggers a severe inflammatory response that can lead to an array of symptoms, including urinary urgency, painfu...
|
- Details
- Ashish Kamat hosts Gottfrid Sjödahl and Fredrik Liedberg to discuss a paper by Sjödahl and Liedberg which studied the different responses to neoadjuvant chemotherapy in urothelial cancer molecular subtypes. The researchers used RNA extraction, gene expression analysis tools, and the Lund taxonomy to identify subtypes and found a statistically significant difference in responses and survival rates....
|
- Details
- Siamak Daneshmand shares insights Phase 2 Study of the "Efficacy and Safety of Erdafitinib in Patients with Bacillus Calmette-Guérin-Unresponsive, High-Risk Non–muscle-Invasive Bladder Cancer with FGFR3/2 Alterations in THOR-2". For patients that present with NMIBC who have carcinoma in situ (CIS), there is a high risk of disease progression. In more advanced bladder cancer FGFR inhibition has dem...
|
- Details
- Ashish Kamat hosts Colin Dinney in a discussion on Adstiladrin Gene Therapy for BCG Unresponsive Disease, highlighting an unmet need for effective second-line therapies for patients suffering from non-muscle invasive bladder cancer. He reveals that the Adstiladrin Phase 3 trial showed promising results, with a complete response rate of 53% for carcinoma in situ (CIS) at three months. Citing its co...
|
- Details
- Sam Chang introduces Timothy Clinton to discuss his groundbreaking work on the genomic characteristics of urothelial carcinoma. Dr. Clinton's research explores the genomic heterogeneity within bladder cancer, specifically focusing on the differences between primary and metastatic patients. His work reveals significant discordance between the primary and metastatic tumors in the same patient, sugge...
|
- Details
- Sam Chang speaks with Tara Cumming and Meredith Donahue who share their insights on implementing an efficient system for administering instillation therapy for bladder cancer patients at Vanderbilt. Cumming and Donahue were instrumental in designing this streamlined process, which they call the BCG Clinic, where patients receive treatment one day each week, improving not just patient care but also...
|
- Details
- Ruchika Talwar hosts a conversation with Brian Chun to discuss Chun's study on the impacts of the BCG drug shortage, a problem that has plagued urologists nationwide for nearly a decade, on the treatment of non-muscle invasive bladder cancer. Chun's research, conducted through a review of Medicare claims data from 2010 to 2017, reveals a decrease in BCG use across the country and a considerable st...
|
